These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20632949)

  • 1. Drug-related cardiotoxicity for the treatment of haematological malignancies in elderly.
    Malato A; Saccullo G; Fazio G; Vergara B; Raso S; Guarneri GP; Russo A; Abbadessa V; Siragusa S
    Curr Pharm Des; 2010; 16(26):2872-9. PubMed ID: 20632949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical value of antracycline toxicity: modern approaches to diagnosis, prevention, and treatment].
    Fandeev OA; Vasechkin SS; Alekhin MN; Odintsov SV; Kallistov VE; Sidorenko BA
    Kardiologiia; 2011; 51(7):40-6. PubMed ID: 21878084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological drugs: classic adverse effects and new clinical evidences.
    Della Pina P; Vizzardi E; Raddino R; Gavazzoni M; Caretta G; Gorga E; Dei Cas L
    Cardiovasc Toxicol; 2012 Dec; 12(4):285-97. PubMed ID: 22661099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maximizing anthracycline tolerability in hematologic malignancies: Treat to each heart's content.
    Oliveira GH; Al-Kindi SG; Caimi PF; Lazarus HM
    Blood Rev; 2016 May; 30(3):169-78. PubMed ID: 26578029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy and Cardiotoxicity in Hematologic Malignancies.
    Stellitano A; Fedele R; Barilla S; Iaria A; Rao CM; Martino M
    Curr Cancer Drug Targets; 2017; 17(4):311-324. PubMed ID: 27903214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiological adverse events after oncological treatment in women.
    Zygulska AL; Krzemieniecki K
    Przegl Lek; 2012; 69(2):87-9. PubMed ID: 22768421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline-induced cardiotoxicity in adult hematologic malignancies.
    Johnson SA
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S22-7. PubMed ID: 16781286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
    Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
    Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors.
    Shah C; Gong Y; Szady A; Sun Q; Pepine CJ; Langaee T; Lucas AR; Moreb JS
    Cardiovasc Toxicol; 2018 Apr; 18(2):184-191. PubMed ID: 29022233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac side effects of chemotherapy: state of art and strategies for a correct management.
    Perrino C; Schiattarella GG; Magliulo F; Ilardi F; Carotenuto G; Gargiulo G; Serino F; Ferrone M; Scudiero F; Carbone A; Trimarco B; Esposito G
    Curr Vasc Pharmacol; 2014 Jan; 12(1):106-16. PubMed ID: 22563720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction to cardiotoxicity review series.
    Force T
    Circ Res; 2010 Jan; 106(1):19-20. PubMed ID: 20056942
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.
    Khouri MG; Douglas PS; Mackey JR; Martin M; Scott JM; Scherrer-Crosbie M; Jones LW
    Circulation; 2012 Dec; 126(23):2749-63. PubMed ID: 23212997
    [No Abstract]   [Full Text] [Related]  

  • 13. Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.
    Cardinale D; Biasillo G; Cipolla CM
    Curr Cardiol Rep; 2016 Jun; 18(6):51. PubMed ID: 27108361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiotoxicity induced by tyrosine kinase inhibitors.
    Orphanos GS; Ioannidis GN; Ardavanis AG
    Acta Oncol; 2009; 48(7):964-70. PubMed ID: 19734999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac complications in cancer treatment - A review.
    Li X; Liu M; Sun R; Zeng Y; Chen S; Zhang P
    Hellenic J Cardiol; 2017; 58(3):190-193. PubMed ID: 28011332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
    Rao AV; Schmader K
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy.
    Ky B; Carver JR
    Heart Fail Clin; 2011 Jul; 7(3):323-31. PubMed ID: 21749884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity of molecularly targeted agents.
    Hedhli N; Russell KS
    Curr Cardiol Rev; 2011 Nov; 7(4):221-33. PubMed ID: 22758623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doppler echocardiography during the follow-up of hematological patients undergoing chemotherapy.
    Marra F; Galderisi M; Camera A; Rinaldi CR; Innelli P; Rotoli B; de Divitiis O
    Int J Cardiol; 2007 Jan; 114(3):403-4. PubMed ID: 16626820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical vignettes: integrated care of cancer patients by oncologists and cardiologists.
    Hofstatter E; Saadati H; Russell K; Russell R
    Curr Cardiol Rev; 2011 Nov; 7(4):258-61. PubMed ID: 22758627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.